Dynamic Susceptibility Contrast MRI in Brain Tumor Evaluation

Dynamic susceptibility contrast MRI involves the rapid acquisition of T2*-weighted images during the first pass of a paramagnetic contrast agent, yielding quantitative maps of cerebral blood volume and flow. These perfusion metrics reflect tumour angiogenesis, vascular permeability and microvascular heterogeneity. The technique is integral to glioma grading, surgical and radiotherapy planning, and monitoring of treatment response, including the differentiation of true progression from post-treatment effects. Advances such as preload dosing, sophisticated leakage-correction algorithms and hybrid spin-echo/gradient-echo acquisitions have improved accuracy and reproducibility. Integration with diffusion imaging and molecular profiling now permits non-invasive identification of regional biologic signatures within infiltrative non-enhancing tumour margins. By offering robust vascular biomarkers, dynamic susceptibility contrast MRI supports personalised therapeutic strategies and informs prognostic modelling on a global scale.

Research from Nature Portfolio

Recent studies have demonstrated the power of combining perfusion metrics with spatially resolved molecular profiling in high-grade glioma. By correlating whole-exome and transcriptomic data from multi-regional biopsies with dynamic susceptibility contrast-derived K2 signature maps, researchers have non-invasively identified cellular phenotypes associated with key genetic alterations such as EGFR amplification and CDKN2A deletion. This integrated approach has revealed distinct microenvironmental zones within non-enhancing tumour regions, enabling predictive models of geographic evolution and offering new avenues for precision-targeted interventions.

Dynamic Susceptibility Contrast MRI in Brain Tumor Evaluation publication trend

The graph below shows the total number of articles in dynamic susceptibility contrast mri in brain tumor evaluation across all publications each year (not limited to Nature Index journals).

Technical terms

Dynamic susceptibility contrast (DSC) MRI: A perfusion technique that measures transient signal changes during contrast passage to map cerebral blood volume and flow.

Relative cerebral blood volume (rCBV): The ratio of blood volume in a tissue region to that in reference tissue, indicating vascular density.

Normalized K2 imaging signature: A DSC-MRI metric capturing the rate of signal recovery after contrast bolus, reflecting cell size heterogeneity.

Dynamic spin-and-gradient-echo echoplanar imaging (SAGE-EPI): A hybrid sequence acquiring both spin-echo and gradient-echo data for simultaneous perfusion and permeability analysis.

Magnetic resonance vascular fingerprinting (MRVF): A method that fits observed DSC-MRI signal patterns to simulated vascular models to estimate microvascular properties.

References

1. Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures. Nature Communications (2023).
2. Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI. European Radiology (2023).
3. MR Vascular Fingerprinting with Hybrid Gradient–Spin Echo Dynamic Susceptibility Contrast MRI for Characterization of Microvasculature in Gliomas. Cancers (2023).
4. Probing the glioma microvasculature: a case series of the comparison between perfusion MRI and intraoperative high-frame-rate ultrafast Doppler ultrasound. European Radiology Experimental (2024).
5. The Role of Preload and Leakage Correction in Gadolinium-Based Cerebral Blood Volume Estimation Determined by Comparison with MION as a Criterion Standard. American Journal of Neuroradiology (2012).
6. Optimized Preload Leakage-Correction Methods to Improve the Diagnostic Accuracy of Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging in Posttreatment Gliomas. American Journal of Neuroradiology (2009).
7. High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques. Frontiers in Oncology (2022).